NCT01028794

Autologous Bone Marrow Mononuclear Cell Transplantation for Stroke Patients

Phase 1/2A Study of Intravenous Autologous Bone Marrow Mononuclear Cell Transplantation for Patients After Cerebral Embolism

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: National Cerebral and Cardiovascular Center, Japan · Academic / Other
• Sex: All
• Age: 20 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether autologous bone marrow mononuclear cells transplantation after stroke is safe and/or effective to improve neurological outcome.

Conditions

• Cerebral Embolism
• Stroke

Interventions

Type	Name	Description
BIOLOGICAL	autologous bone marrow mononuclear cells	intravenous administration of autologous bone marrow derived mononuclear cells obtained from 25ml of bone marrow on day 7-10 after stroke (only once in that period)
BIOLOGICAL	autologous bone marrow mononuclear cells	intravenous administration of autologous bone marrow derived mononuclear cells obtained from 50ml of bone marrow on day 7-10 after stroke (only once in that period)

Timeline

• Start date: 2008-05-01
• Primary completion: 2013-07-01
• Completion: 2013-07-01
• First posted: 2009-12-09
• Last updated: 2013-07-08

Locations

1 site across 1 country: Japan